Related Experiment Video
Updated: Apr 11, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Pancreatic cancer: emerging small molecule pharmacotherapies
Barbara Pokora1, Kacper Pokora1, Jakub Fichna1
1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, driven by aggressive tumor biology, therapeutic resistance, and activation of oncogenic KRAS. Despite advances in chemotherapy, effective targeted treatment options have been lacking, positioning PDAC as an unmet medical need in oncology.
Areas Covered:
This review examines progress in small-molecule pharmacotherapy for PDAC, with a focus on emerging KRAS-directed agents, including G12D-selective inhibitors and alternative KRAS-targeting strategies, as well as downstream inhibition of MAPK and PI3K signaling. In addition, the review discusses adaptive vulnerabilities that sustain KRAS-driven tumors, including non-oncogene addiction to cell-cycle regulation, DNA damage response pathways, transcriptional plasticity, and metabolic rewiring.The analysis integrates evidence from preclinical studies and early-phase clinical trials identified through a comprehensive literature search of PubMed and ClinicalTrials.gov for English-language articles published between January 2005 and December 2025, using keywords related to PDAC and small-molecule pharmacotherapy.
Expert Opinion:
The field is transitioning from single-pathway inhibition toward rational, biomarker-guided combination strategies aimed at disabling adaptive survival networks rather than KRAS signaling alone. Future success of PDAC pharmacotherapy will depend on improved patient selection, validation of predictive biomarkers, and innovative clinical trial designs capable of balancing efficacy with the toxicity of multi-agent regimens.
Insights
Pancreatic cancer (PDAC) treatment is advancing with new KRAS-targeted therapies and combination strategies. Research focuses on overcoming resistance by targeting adaptive vulnerabilities for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacotherapy
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited targeted treatment options.
- Oncogenic KRAS mutations drive PDAC aggressiveness and therapeutic resistance.
- Current chemotherapy offers limited efficacy, highlighting an unmet medical need.
Purpose of the Study:
- To review progress in small-molecule pharmacotherapy for PDAC.
- To focus on emerging KRAS-directed agents and downstream signaling inhibition.
- To discuss adaptive vulnerabilities in KRAS-driven tumors.
Main Methods:
- Comprehensive literature search of PubMed and ClinicalTrials.gov (2005-2025).
- Analysis of preclinical studies and early-phase clinical trials.
- Keywords: PDAC, small-molecule pharmacotherapy, KRAS inhibitors, MAPK, PI3K.
Main Results:
- Emerging KRAS-directed agents (e.g., G12D-selective inhibitors) show promise.
- Downstream signaling inhibition (MAPK, PI3K) is a key therapeutic strategy.
- Adaptive vulnerabilities (cell-cycle, DNA damage, metabolism) sustain tumors.
Conclusions:
- The field is shifting towards combination strategies targeting adaptive networks beyond KRAS.
- Biomarker-guided patient selection and innovative trial designs are crucial.
- Balancing efficacy and toxicity in multi-agent regimens is essential for future success.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...